Can-Fite BioPharma Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CANF NYSE American 2836 www.canfite.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Can-Fite BioPharma Ltd.

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market - May 18th, 2026 5:00 am
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy - May 13th, 2026 5:00 am
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months - Apr 30th, 2026 6:31 am
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - Mar 30th, 2026 5:20 am
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - Mar 26th, 2026 7:27 am
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance - Mar 17th, 2026 5:47 am
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Mar 5th, 2026 7:18 am
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - Mar 4th, 2026 8:25 am
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study - Mar 4th, 2026 5:00 am
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson - Feb 17th, 2026 5:00 am
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy - Feb 9th, 2026 5:00 am
Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson - Feb 5th, 2026 5:00 am
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson - Jan 20th, 2026 5:00 am
Sector Update: Health Care Stocks Edge Higher Late Afternoon - Dec 26th, 2025 2:06 pm
Sector Update: Health Care Stocks Lower in Friday Afternoon Trading - Dec 26th, 2025 11:59 am
Top Midday Stories: Nvidia-Groq Licensing Deal; Target Attracts Growing Interest From Toms Capital - Dec 26th, 2025 10:10 am
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction - Dec 26th, 2025 5:00 am
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change - Dec 23rd, 2025 2:46 pm
Can-Fite Provides Update on Clinical and Financial Status - Dec 16th, 2025 7:19 am
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Nov 26th, 2025 5:00 am